Results 31 to 40 of about 225,165 (200)

The PTP1B Inhibitor Trodusquemine (MSI-1436) Improves Glucose Uptake in Equine Metabolic Syndrome Affected Liver through Anti-Inflammatory and Antifibrotic Activity. [PDF]

Int J Inflam, 2023
Background Hyperactivation of protein tyrosine phosphatase (PTP1B) has been associated with several metabolic malfunctions ranging from insulin resistance, metaflammation, lipotoxicity, and hyperglycaemia.
Bourebaba L, Serwotka-Suszczak A, Bourebaba N, Zyzak M, Marycz K.   +4 more
europepmc   +2 more sources

Obesity-Related Metabolic Dysfunction in Dairy Cows and Horses: Comparison to Human Metabolic Syndrome

Life, 2021
Obesity has become a serious health problem with frequent occurrence both in human and animal populations. It is estimated that it may affect over 85% of the human population and 70–80% of horses and cows by 2030.
Zsofia Daradics, Cristian M. Crecan, Mirela A. Rus, Iancu A. Morar, Mircea V. Mircean, Adriana Florinela Cătoi, Andra Diana Cecan, Cornel Cătoi   +7 more
doaj   +2 more sources

The PTP1B inhibitor MSI-1436 ameliorates liver insulin sensitivity by modulating autophagy, ER stress and systemic inflammation in Equine metabolic syndrome affected horses. [PDF]

Front Endocrinol (Lausanne), 2023
Background Equine metabolic syndrome (EMS) is a multifactorial pathology gathering insulin resistance, low-grade inflammation and past or chronic laminitis.
Bourebaba L, Serwotka-Suszczak A, Pielok A, Sikora M, Mularczyk M, Marycz K.   +5 more
europepmc   +2 more sources

Human Adenovirus 36 Antibodies in Horses with Different Metabolic Statuses [PDF]

Animals
This study investigated the presence of antibodies to human adenovirus type 36 (HAdV-D36) in horses with different metabolic statuses, including normal, overweight, and those diagnosed with equine metabolic syndrome (EMS).
Aleksandra Chwirot, Artur Niedźwiedź, Dominika Stygar, Natalia Siwińska, Marzena Paszkowska, Wojciech Niżański, Skarlet Napierkowska, Paweł Migdał, Agata Kublicka, Maja Marynowska, Anna Matczuk, Devon Fuller, Barbara Bażanów   +12 more
doaj   +2 more sources

In Vitro Generated Equine Hepatic-Like Progenitor Cells as a Novel Potent Cell Pool for Equine Metabolic Syndrome (EMS) Treatment. [PDF]

Stem Cell Rev Rep, 2023
Equine metabolic syndrome (EMS) is recognized as one of the leading cause of health threatening in veterinary medicine worldwide. Recently, PTP1B inhibition has been proposed as an interesting strategy for liver insulin resistance reversion in both ...
Marycz K, Bourebaba N, Serwotka-Suszczak A, Mularczyk M, Galuppo L, Bourebaba L.   +5 more
europepmc   +2 more sources

Sex hormone-binding globulin (SHBG) mitigates ER stress and improves viability and insulin sensitivity in adipose-derived mesenchymal stem cells (ASC) of equine metabolic syndrome (EMS)-affected horses. [PDF]

Cell Commun Signal, 2023
Background Equine metabolic syndrome (EMS), which encompasses insulin resistance, low-grade inflammation and predisposition to laminitis is a critical endocrine disorder among the most prevalent conditions affecting horses from different breeds ...
Bourebaba N, Sikora M, Qasem B, Bourebaba L, Marycz K.   +4 more
europepmc   +2 more sources

Heritability of metabolic traits associated with equine metabolic syndrome in Welsh ponies and Morgan horses.

Equine Veterinary Journal, 2018
BACKGROUND Equine metabolic syndrome (EMS) is a complex clinical disorder with both environmental and genetic factors contributing to EMS phenotypes.
E. Norton, N. Schultz, A. Rendahl, D. McFarlane, R. Geor, J. Mickelson, M. McCue   +6 more
semanticscholar   +4 more sources

Associations between endocrine disrupting chemicals and equine metabolic syndrome phenotypes [PDF]

Chemosphere, 2019
Elaine M Norton, Aaron Rendahl, R J Geor   +2 more
exaly   +2 more sources

The effect of insulin infusion on heart rate and systemic blood pressure in horses with equine metabolic syndrome

Equine Veterinary Journal, 2019
Background There is little evidence that horses with equine metabolic syndrome (EMS) have higher resting blood pressures than horses with normal insulin sensitivity.
Truelsen Lindåse, Sanna,, Sveriges lantbruksuniversitet., Nostell, Katarina,, Bröjer, Johan,   +3 more
core   +2 more sources

Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue [PDF]

BMC Veterinary Research
Background Insulin dysregulation is a hallmark of equine metabolic syndrome (EMS), and in recent years, pharmacological treatment with sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have shown promise in reducing the risk of hyperinsulinemia ...
Camilla Anger-Håål, Cathrine T. Fjordbakk, Carl Ekstrand, Fredrik S. Skedsmo, Runa Rørtveit   +4 more
doaj   +2 more sources